| Two phase 3 trials of dupilumab versus placebo in atopic dermatitis EL Simpson, T Bieber, E Guttman-Yassky, LA Beck, A Blauvelt, MJ Cork, ... New England Journal of Medicine 375 (24), 2335-2348, 2016 | 1727 | 2016 |
| Dupilumab treatment in adults with moderate-to-severe atopic dermatitis LA Beck, D Thaçi, JD Hamilton, NM Graham, T Bieber, R Rocklin, JE Ming, ... New England Journal of Medicine 371 (2), 130-139, 2014 | 1449 | 2014 |
| Th17 cytokines interleukin (IL)‐17 and IL‐22 modulate distinct inflammatory and keratinocyte‐response pathways KE Nograles, LC Zaba, E Guttman‐Yassky, J Fuentes‐Duculan, ... British Journal of Dermatology 159 (5), 1092-1102, 2008 | 961 | 2008 |
| Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis JK Gittler, A Shemer, M Suárez-Fariñas, J Fuentes-Duculan, KJ Gulewicz, ... Journal of Allergy and Clinical Immunology 130 (6), 1344-1354, 2012 | 952 | 2012 |
| IL-22–producing “T22” T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17–producing TH17 T cells KE Nograles, LC Zaba, A Shemer, J Fuentes-Duculan, I Cardinale, ... Journal of Allergy and Clinical Immunology 123 (6), 1244-1252. e2, 2009 | 748 | 2009 |
| Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis A Chiricozzi, E Guttman-Yassky, M Suárez-Farinas, KE Nograles, S Tian, ... Journal of Investigative Dermatology 131 (3), 677-687, 2011 | 698 | 2011 |
| The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies PM Brunner, E Guttman-Yassky, DYM Leung Journal of Allergy and Clinical Immunology 139 (4), S65-S76, 2017 | 595 | 2017 |
| Anti–interleukin-31 receptor A antibody for atopic dermatitis T Ruzicka, JM Hanifin, M Furue, G Pulka, I Mlynarczyk, A Wollenberg, ... New England Journal of Medicine 376 (9), 826-835, 2017 | 595 | 2017 |
| Cellular and molecular immunologic mechanisms in patients with atopic dermatitis T Werfel, JP Allam, T Biedermann, K Eyerich, S Gilles, E Guttman-Yassky, ... Journal of allergy and clinical immunology 138 (2), 336-349, 2016 | 588 | 2016 |
| The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization S Noda, M Suárez-Fariñas, B Ungar, SJ Kim, C de Guzman Strong, H Xu, ... Journal of Allergy and Clinical Immunology 136 (5), 1254-1264, 2015 | 554 | 2015 |
| Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches DYM Leung, E Guttman-Yassky Journal of Allergy and Clinical Immunology 134 (4), 769-779, 2014 | 518 | 2014 |
| Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis E Guttman-Yassky, R Bissonnette, B Ungar, M Suárez-Fariñas, ... Journal of Allergy and Clinical Immunology 143 (1), 155-172, 2019 | 516 | 2019 |
| Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis M Suárez-Fariñas, N Dhingra, J Gittler, A Shemer, I Cardinale, ... Journal of Allergy and Clinical Immunology 132 (2), 361-370, 2013 | 492 | 2013 |
| Atopic dermatitis endotypes and implications for targeted therapeutics T Czarnowicki, H He, JG Krueger, E Guttman-Yassky Journal of Allergy and Clinical Immunology 143 (1), 1-11, 2019 | 483 | 2019 |
| Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis JD Hamilton, M Suárez-Farinas, N Dhingra, I Cardinale, X Li, A Kostic, ... Journal of Allergy and Clinical Immunology 134 (6), 1293-1300, 2014 | 475 | 2014 |
| Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities M Suárez-Fariñas, SJ Tintle, A Shemer, A Chiricozzi, K Nograles, ... Journal of Allergy and Clinical Immunology 127 (4), 954-964. e4, 2011 | 465 | 2011 |
| Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2) A Wollenberg, A Blauvelt, E Guttman‐Yassky, M Worm, C Lynde, ... British Journal of Dermatology 184 (3), 437-449, 2021 | 406 | 2021 |
| Contrasting pathogenesis of atopic dermatitis and psoriasis—part I: clinical and pathologic concepts E Guttman-Yassky, KE Nograles, JG Krueger Journal of Allergy and Clinical Immunology 127 (5), 1110-1118, 2011 | 404 | 2011 |
| Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis E Guttman-Yassky, MA Lowes, J Fuentes-Duculan, LC Zaba, I Cardinale, ... The Journal of Immunology 181 (10), 7420-7427, 2008 | 402 | 2008 |
| Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial EL Simpson, AS Paller, EC Siegfried, M Boguniewicz, L Sher, ... JAMA dermatology 156 (1), 44-56, 2020 | 401 | 2020 |
